• Corpus ID: 53535815

The clinical DELTA-P score accurately predicts small cell lung cancer in the Lambert-Eaton myasthenic syndrome

  title={The clinical DELTA-P score accurately predicts small cell lung cancer in the Lambert-Eaton myasthenic syndrome},
  author={M. J. Titulaer and Paul Maddison and J K Sont and P. W. Wirtz and David Hilton‐Jones and Rinse Klooster and Nick Willcox and Marko Potman and P. Sillevis Smitt and Jbm Kuks and B. O. Roep and Angela Vincent and S. M. van der Maarel and J. B. Van Dijk and Bethan Lang and J. J. Verschuuren},
Introduction Approximately one half of patients with Lambert-Eaton myasthenic syndrome (LEMS) have small cell lung carcinomas (SCLC), aggressive tumours with poor prognosis. In view of its profound impact on therapy and survival, we developed and validated a score to identify the presence of SCLC early in the course of LEMS. Patients and methods We derived a prediction score for SCLC in LEMS in a nationwide cohort of 107 Dutch patients, and validated it in a similar cohort of 112 British… 

Figures and Tables from this paper



Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome.

PURPOSE A small-cell lung carcinoma (SCLC) is found in 50% of patients with Lambert-Eaton myasthenic syndrome (LEMS). We evaluated screening to optimize screening strategy for SCLC. It is important

SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival.

SOX antibodies have diagnostic value in discriminating SCLC-LEMS from nontumor LEMS, but have no relation to survival in patients with SclC.

Lambert–Eaton myasthenic syndrome has a more progressive course in patients with lung cancer

The presence of a particular symptom associated with LEMS did not predict the presence of SCLC, but in patients with rapidly progressive LEMS the possibility of underlying lung cancer should be of particular concern.

Lambert–Eaton Myasthenic Syndrome

Data support a role for the LEMS‐related immune response in suppressing the tumor activity and compare the clinical and laboratory characteristics of tumor and nontumor related LEMS patients.

The Lambert–Eaton myasthenic syndrome 1988–2008: A clinical picture in 97 patients

The epidemiology of the Lambert-Eaton myasthenic syndrome in the Netherlands

The Lambert-Eaton myasthenic syndrome (LEMS) is presumed to be rare, but epidemiologic studies in large circumscribed populations have not been performed, and the prevalence and incidence of LEMS and the frequency of underlying SCLC in the Netherlands is established.

SOX1 antibodies are markers of paraneoplastic Lambert–Eaton myasthenic syndrome

The detection of SOX1 antibodies in patients with Lambert–Eaton myasthenic syndrome (LEMS) predicts the presence of small cell lung cancer and may be used to follow more closely those LEMS patients with no evidence of cancer at the initial workup.

HLA class I and II in Lambert-Eaton myasthenic syndrome without associated tumor.